Trial Profile
A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 03 Apr 2018 Planned End Date changed from 1 Dec 2022 to 20 Nov 2017.
- 03 Apr 2018 Planned primary completion date changed from 1 Dec 2020 to 20 Nov 2017.
- 03 Apr 2018 Planned initiation date changed from 1 Sep 2016 to 4 Nov 2016.